JP2023052214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023052214A5 JP2023052214A5 JP2023000416A JP2023000416A JP2023052214A5 JP 2023052214 A5 JP2023052214 A5 JP 2023052214A5 JP 2023000416 A JP2023000416 A JP 2023000416A JP 2023000416 A JP2023000416 A JP 2023000416A JP 2023052214 A5 JP2023052214 A5 JP 2023052214A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 97
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 13
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 13
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 13
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000004860 Blast Crisis Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000001608 potassium adipate Substances 0.000 claims 1
- 239000001601 sodium adipate Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025002125A JP2025061059A (ja) | 2017-02-20 | 2025-01-07 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461145P | 2017-02-20 | 2017-02-20 | |
| US62/461,145 | 2017-02-20 | ||
| PCT/US2018/018768 WO2018152516A1 (en) | 2017-02-20 | 2018-02-20 | Proteins binding cd33, nkg2d and cd16 |
| JP2019545316A JP2020510646A (ja) | 2017-02-20 | 2018-02-20 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545316A Division JP2020510646A (ja) | 2017-02-20 | 2018-02-20 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002125A Division JP2025061059A (ja) | 2017-02-20 | 2025-01-07 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023052214A JP2023052214A (ja) | 2023-04-11 |
| JP2023052214A5 true JP2023052214A5 (enExample) | 2023-08-23 |
Family
ID=63169992
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545316A Pending JP2020510646A (ja) | 2017-02-20 | 2018-02-20 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2023000416A Pending JP2023052214A (ja) | 2017-02-20 | 2023-01-05 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2025002125A Pending JP2025061059A (ja) | 2017-02-20 | 2025-01-07 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545316A Pending JP2020510646A (ja) | 2017-02-20 | 2018-02-20 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002125A Pending JP2025061059A (ja) | 2017-02-20 | 2025-01-07 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210130471A1 (enExample) |
| EP (1) | EP3583131A4 (enExample) |
| JP (3) | JP2020510646A (enExample) |
| KR (1) | KR20190120775A (enExample) |
| CN (1) | CN110573530A (enExample) |
| AU (1) | AU2018220734B2 (enExample) |
| BR (1) | BR112019017277A2 (enExample) |
| CA (1) | CA3054078A1 (enExample) |
| IL (1) | IL268790A (enExample) |
| MA (1) | MA47508A (enExample) |
| SG (1) | SG11201907638QA (enExample) |
| WO (1) | WO2018152516A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3235295C (en) | 2017-02-20 | 2024-11-19 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| US12215157B2 (en) | 2018-02-20 | 2025-02-04 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| KR20210089712A (ko) * | 2018-11-07 | 2021-07-16 | 크리스퍼 테라퓨틱스 아게 | 항-cd33 면역세포 암 치료법 |
| CN113121697B (zh) * | 2019-12-31 | 2023-06-09 | 周易 | Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用 |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| EP4175656A4 (en) * | 2020-07-03 | 2024-10-16 | The Trustees of Columbia University in the City of New York | POLYFUNCTIONAL ORTHOGONAL PROTEIN CHIMERA |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN115197330B (zh) * | 2021-04-14 | 2023-04-28 | 广州百暨基因科技有限公司 | 同时靶向cll1和cd33的嵌合抗原受体及其应用 |
| CN116948029A (zh) * | 2022-04-20 | 2023-10-27 | 南京融捷康生物科技有限公司 | 一种包含IgG类Fc区变体的抗体及其用途 |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025245271A1 (en) * | 2024-05-21 | 2025-11-27 | Dragonfly Therapeutics, Inc. | Anti-nkg2d antibodies and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL151873A0 (en) * | 2000-03-24 | 2003-04-10 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| CA3102679A1 (en) * | 2007-12-14 | 2009-06-25 | Birgitte Urso | Antibodies against human nkg2d and uses thereof |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| JP6594855B2 (ja) * | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| WO2014198748A1 (en) * | 2013-06-11 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| EP3126384B1 (en) * | 2014-04-01 | 2020-12-02 | Adimab, LLC | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
| TN2016000525A1 (en) * | 2014-05-29 | 2018-04-04 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| EP2985294A1 (en) * | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| JP6919118B2 (ja) * | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| ES2717308T3 (es) * | 2014-12-06 | 2019-06-20 | Gemoab Monoclonals Gmbh | Células madre pluri- o multi-potentes genéticamente modificadas y sus usos |
| US10973914B2 (en) * | 2015-02-20 | 2021-04-13 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| EP4424326A3 (en) * | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| WO2016207273A2 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific antigen binding proteins |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| IL268554B2 (en) * | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
-
2018
- 2018-02-20 EP EP18753685.9A patent/EP3583131A4/en active Pending
- 2018-02-20 US US16/486,921 patent/US20210130471A1/en not_active Abandoned
- 2018-02-20 WO PCT/US2018/018768 patent/WO2018152516A1/en not_active Ceased
- 2018-02-20 SG SG11201907638QA patent/SG11201907638QA/en unknown
- 2018-02-20 AU AU2018220734A patent/AU2018220734B2/en not_active Expired - Fee Related
- 2018-02-20 CA CA3054078A patent/CA3054078A1/en active Pending
- 2018-02-20 MA MA047508A patent/MA47508A/fr unknown
- 2018-02-20 CN CN201880026148.9A patent/CN110573530A/zh active Pending
- 2018-02-20 BR BR112019017277-7A patent/BR112019017277A2/pt unknown
- 2018-02-20 JP JP2019545316A patent/JP2020510646A/ja active Pending
- 2018-02-20 KR KR1020197026921A patent/KR20190120775A/ko not_active Ceased
-
2019
- 2019-08-19 IL IL26879019A patent/IL268790A/en unknown
-
2023
- 2023-01-05 JP JP2023000416A patent/JP2023052214A/ja active Pending
-
2025
- 2025-01-07 JP JP2025002125A patent/JP2025061059A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023052214A5 (enExample) | ||
| JP2023106433A5 (enExample) | ||
| JP2020510646A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021098732A5 (enExample) | ||
| JP2021098733A5 (enExample) | ||
| JP2020507328A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| JP2023029988A5 (enExample) | ||
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| JP2020529410A5 (enExample) | ||
| JP2020507577A5 (enExample) | ||
| JP2020521448A5 (enExample) | ||
| JP2020184996A5 (enExample) | ||
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 | |
| US5945311A (en) | Method for producing heterologous bi-specific antibodies | |
| JP2020522473A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2020522474A5 (enExample) | ||
| JPWO2020033587A5 (enExample) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2018046872A5 (enExample) | ||
| JP2024167313A5 (enExample) | ||
| JPWO2020033702A5 (enExample) | ||
| JPWO2021076564A5 (enExample) |